Sarepta Therapeutics Inc (SRPT)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$21.30

Buy

$21.53

arrow-down$-0.22 (-1.01%)

Prices updated at 13 Dec 2025, 00:59 EST

Prices minimum 15 mins delay

Prices in USD

Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

-

CEO

Mr. Douglas S. Ingram,Esq.

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

1,372

Head office

215 First Street

Cambridge

United States

02142

+1 617 274-4000

iestepan@sarepta.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Douglas S. Ingram,Esq. Director and Chief Executive Officer	0.85m
Ms. Louise Rodino-Klapac, PhD President, Research and Development and Technical Operations	0.67m
Mr. Ian Michael Estepan President and Chief Operating Officer	0.66m
Mr. Ryan Wong Executive Vice President, Chief Financial Officer and Principal Accounting Officer	-
Ms. Deirdre P. Connelly Independent Director	0.02m
Dr. M. Kathleen Behrens Wilsey, PhD Chairwoman of the Board	0.13m
Dr. Claude Nicaise,M.D. Independent Director	0.08m
Dr. Hans Wigzell, M.D.,PhD Independent Director	0.09m
Mr. Richard J. Barry Independent Director	0.11m
Dr. Kathryn Jean Boor, PhD Independent Director	0.08m
Dr. Stephen L. Mayo, PhD Independent Director	0.08m
Mr. Michael A. Chambers Independent Director	0.07m
Mr. Dallan Murray Executive Vice President and Chief Customer Officer	0.62m
Ms. Cristin L. Rothfuss Executive Vice President, Chief General Counsel and Corporate Secretary	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	13,199,845
Vanguard Group Inc	9,160,179
BlackRock Fund Advisors	9,052,929
CAPITAL INTERNATIONAL INVESTORS	6,363,590
iShares Core S&P Small-Cap ETF	5,828,222

Director dealings

Date chevron-l-regular chevron-r-regular	Action
27 Dec 2024	-
12 Dec 2024	-
12 Dec 2024	-
12 Dec 2024	-
05 Dec 2024	-
26 Nov 2024	-
26 Nov 2024	-
18 Nov 2024	-
12 Sep 2024	-
12 Sep 2024	-
04 Sep 2024	-
30 Aug 2024	-
16 Aug 2024	-
16 Aug 2024	-
16 Aug 2024	-
03 Jul 2024	-
03 Jul 2024	-
21 Jun 2024	-
21 Jun 2024	-
21 Jun 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.